Enanta Pharmaceuticals Inc (ENTA) stock
Close on Nov 11, 2026Market cap $337.86MP/E –Yield –
Enanta Pharmaceuticals Inc reported revenue of $65.26M for the twelve months to Jun 30, 2026. Free cash flow was -$36.94M. At the latest close the market valued the company at $337.86M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $337.86M
- P/E ratio
- –
- Price to sales
- 5.18
- Price to book
- 3.34
- Dividend yield
- –
- Free cash flow yield
- -10.93%
Fundamentals
- Revenue
- $65.26M
- Net income
- -$63.23M
- EPS, diluted
- -$3.84
- Free cash flow
- -$36.94M
- Book value per share
- $3.47
- Diluted shares
- 29M
Trading
- Next earnings
- Nov 16, 2026 (estimated, during market hours)
- Previous close
- $11.22
- Open
- $11.35
- Day's range
- $11.17 – $11.70
- Volume
- 208,855
- Average volume (20 days)
- 265,120
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.15
- 52-week range
- $10.05 – $17.15
- RSI (14 days)
- 51.5
- Volatility (1 year)
- 49.4%
- Relative volume
- 0.89×
- WACC
- 10.6%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENTA | S&P 500 | Difference | ENTA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.2% | -2.4% | −4.8 pts | ||
| 3 months | -14.2% | -1.2% | −13.1 pts | ||
| Year to date | -26.4% | +12.3% | −38.7 pts | ||
| 1 year | -3.7% | +12.4% | −16.1 pts | ||
| 3 years | +40.4% | +78.8% | −38.4 pts | +12.0% | +21.4% |
| 5 years | -87.2% | +75.2% | −162.4 pts | -33.8% | +11.9% |
| 10 years | -58.8% | +311.1% | −369.9 pts | -8.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Enanta Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for theUpdate
- Update
- Results
- Results
About Enanta Pharmaceuticals
Pharmaceutical Preparations
Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule oral drug candidates for virology and immunology indications. Within virology, the company discovered glecaprevir, an antiviral protease inhibitor co-formulated in AbbVie's combination treatments for hepatitis C virus, and develops clinical-stage candidates targeting respiratory syncytial virus, COVID-19, and hepatitis B virus. In immunology, Enanta targets biological mechanisms such as KIT and STAT6 to design therapies for type 2 inflammatory diseases, focusing proof-of-concept efforts on conditions such as chronic spontaneous urticaria and atopic dermatitis. The company engages in collaborative partnerships and utilizes contract research organizations for development and commercialization.
Company profile, executives and historyEnanta Pharmaceuticals stock: common questions
What is Enanta Pharmaceuticals's stock price?
ENTA closed at $11.60 on Nov 11, 2026, up 3.39% on the day. Over the past 52 weeks it traded between $10.05 and $17.15.
What is Enanta Pharmaceuticals's market cap?
Enanta Pharmaceuticals was worth $337.86M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ENTA's P/E ratio?
Enanta Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$3.84), so it has no meaningful P/E ratio.
How much revenue does Enanta Pharmaceuticals make?
Enanta Pharmaceuticals reported revenue of $65.26M for the twelve months to Jun 30, 2026.
Does Enanta Pharmaceuticals pay a dividend?
No. Enanta Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Enanta Pharmaceuticals report earnings next?
Enanta Pharmaceuticals is expected to report Q4 FY2026 results on Nov 16, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ENTA stock performed over the past year?
Including dividends, ENTA returned -3.7% over the past year, against +12.4% for the S&P 500.
How many ENTA shares are sold short?
2M shares were sold short at the latest FINRA report, 6.92% of the float, or 7.6 days of average trading volume.
Who are Enanta Pharmaceuticals's competitors?
Companies most similar to Enanta Pharmaceuticals by business, industry and size include ASMB, SEPN, XLO, WVE, FBIO.
See a number that looks wrong?